Milestones in lymphangioleiomyomatosis research.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Lymphangioleiomyomatosis with Tuberous Sclerosis Complex-A Case Study.Journal of personalized medicine · 2023
   Article
2. Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management.Current treatment options in cardiovascular medicine · 2017
   Review
3. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.Virchows Archiv : an international journal of pathology · 2014
   Article
4. Lymphangioleiomyomatosis: current and future.Journal of thoracic disease · 2013
   Article
5. Adolescent form of sporadic lymphangioleiomyomatosis (S-LAM).Allergologia et immunopathologia
   Article
6. A Study on the Psychological Profile and Coping With the Disease in Patients With Lymphangioleiomyomatosis.Open respiratory archives
   Article

Corrections and comments

• Comment on
  Lymphangioleiomyomatosis: what do we know and what are we looking for?2011

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as